证券代码：002675 证券简称：东诚药业 公告编号：2025-021 第六届董事会第十次会议决议公告 2025年4月29日，烟台东诚药业集团股份有限公司（以下简称"公司"）在 山东省烟台经济技术开发区长白山路7号公司会议室召开了第六届董事会第十次 会议。会议通知于2025年4月25日以通讯方式送达。会议采用现场结合通讯方式 召开，会议应到董事5人，实到董事5人。公司全体监事和高级管理人员列席了本 次会议。会议由公司董事长由守谊先生主持，会议召开符合《中华人民共和国公 司法》（以下简称"《公司法》"）及《烟台东诚药业集团股份有限公司章程》 （以下简称"《公司章程》"）等有关规定。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 烟台东诚药业集团股份有限公司 一、董事会会议召开情况 （一）审议通过了《2025年第一季度报告》 内容详见刊载于《证券时报》、《证券日报》、《中国证券报》、《上海证 券报》和巨潮资讯网（www.cninfo.com.cn）《2025年第一季度报告》。 本议案已经公司董事会审计委员会审议通过。 表决结果：同意 5 票，反对 0 票，弃权 ...

Group 1 - The company Dongcheng Pharmaceutical plans to acquire 1.65% equity stake from a minority shareholder of its subsidiary Yantai Lannacheng Biotechnology Co., Ltd. for approximately 36 million RMB [1] - The acquisition is aimed at consolidating control over the subsidiary, which may enhance operational efficiency and strategic alignment [1] - This move reflects the company's ongoing strategy to strengthen its position in the biotechnology sector [1]

Financial Performance - The company's revenue for Q1 2025 was CNY 686.93 million, representing a year-on-year increase of 6.13% compared to CNY 647.23 million in the same period last year[5]. - Net profit attributable to shareholders decreased by 61.55% to CNY 24.73 million from CNY 64.33 million year-on-year[5]. - Total operating revenue for the current period reached ¥686,928,164.92, an increase of 6.1% compared to ¥647,229,057.46 in the previous period[21]. - Net profit for the current period was ¥17,149,804.60, a decrease of 74.0% from ¥65,930,939.61 in the previous period[22]. - The profit attributable to the parent company's shareholders was ¥24,731,523.19, down from ¥64,327,510.75, representing a decline of 61.6%[22]. - Total comprehensive income for the period was CNY 14,432,666.35, a decrease from CNY 64,043,153.93 in the previous period[23]. - Basic and diluted earnings per share were both CNY 0.0300, down from CNY 0.0780 in the previous period[23]. Cash Flow and Financial Position - The net cash flow from operating activities increased significantly by 168.98%, reaching CNY 114.04 million, compared to a negative cash flow of CNY 165.32 million in the previous year[5]. - Net cash flow from operating activities was CNY 114,036,490.30, a significant improvement from a negative CNY 165,318,835.72 in the previous period[25]. - Cash inflow from investment activities totaled CNY 244,977,797.84, compared to CNY 55,664,969.52 in the previous period[25]. - Net cash flow from financing activities was negative CNY 105,346,407.51, a decline from a positive CNY 577,121,865.51 in the previous period[25]. - The ending balance of cash and cash equivalents was CNY 670,718,795.06, slightly up from CNY 668,932,589.63 in the previous period[25]. - The company’s cash and cash equivalents decreased from 755,972,381.28 CNY to 697,376,537.69 CNY, reflecting a decline of approximately 7.5%[17]. - The company reported a total cash outflow from operating activities of CNY 591,630,360.78, down from CNY 824,778,062.09 in the previous period[25]. Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 8.69 billion, a 0.61% increase from CNY 8.63 billion at the end of the previous year[5]. - Total assets increased to ¥8,686,979,590.40 from ¥8,634,677,996.44, showing a growth of 0.6%[19]. - Total liabilities rose to ¥3,287,098,674.03, slightly up from ¥3,263,210,041.55, indicating an increase of 0.7%[19]. - Current liabilities decreased to ¥1,542,348,228.08 from ¥1,753,956,120.72, a reduction of 12.0%[19]. - Non-current liabilities increased to ¥1,744,750,445.95 from ¥1,509,253,920.83, reflecting a rise of 15.6%[19]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 21,576, with no preferred shareholders[12]. - The company reported a total of 27,654,757 shares held by PACIFIC RAINBOW INTERNATIONAL, accounting for 3.35% of total shares[14]. - The top ten unrestricted shareholders collectively hold 124,888,049 shares, with Yantai Dongyi Biological Engineering Co., Ltd. being the largest shareholder[14]. Operational Segments - The sales revenue from the raw material drug segment was CNY 321.50 million, up 11.10% year-on-year, primarily due to increased sales of heparin products[9]. - The sales revenue from the formulation segment decreased by 6.78% to CNY 86.63 million, while the nuclear medicine segment saw a slight decline of 0.63% to CNY 231.20 million[13]. Expenses and Financial Management - The company reported a significant increase in financial expenses by 536.48%, attributed to increased interest expenses from equity financing repurchase and reduced exchange gains[13]. - Research and development expenses were ¥44,008,471.83, slightly down from ¥45,209,265.30, a decrease of 2.7%[22]. - The company paid CNY 168,579,902.52 to employees, an increase from CNY 152,583,106.37 in the previous period[25]. - The company experienced a 271.36% increase in credit impairment losses, primarily due to provisions for bad debts on receivables[13]. Future Outlook - The company is currently exploring market expansion opportunities and new product development strategies[15].

烟台东诚药业集团股份有限公司 第六届董事会第三次独立董事专门会议 一、独立董事专门会议召开情况 2025 年 4 月 29 日，烟台东诚药业集团股份有限公司（以下简称"公司"） 召开了第六届董事会第三次独立董事专门会议。会议通知于 2025 年 4 月 25 日以 通讯方式送达，会议应出席独立董事 2 人，实际出席独立董事 2 人，会议的召集、 召开和表决程序符合《公司章程》、《上市公司独立董事管理办法》、《独立董事工 作制度》等规定。 二、会议审议情况 全体独立董事经过审议，审议通过了如下议案： 一、《关于购买控股子公司少数股东股权暨关联交易的议案》 经审核，我们认为：公司本次购买景林景盈所持有的蓝纳成的股份事项，交 易价格根据《增资协议》、《股东协议》及交易各方共同协商确定，不存在损害公 司及公司股东利益的情形。 表决结果：同意 2 票，反对 0 票，弃权 0 票。 独立董事：李方、赵大勇 2025 年 4 月 29 日 ...

证券代码：002675 证券简称：东诚药业 公告编号：2025-020 烟台东诚药业集团股份有限公司 2024 年度股东大会决议公告 一、会议召开情况 （一）召开时间： 现场会议时间：2025年3月28日（星期五）14:30； 网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间为： 2025年3月28日9:15－9:25，9:30－11:30，13:00－15:00；通过深圳证券交易所 互联网投票系统投票的具体时间为：2025年3月28日9:15-15:00期间的任意时间。 （二）现场会议地点：烟台经济技术开发区长白山路7号公司会议室； （六）本次股东大会的召集、召开程序符合《公司法》《上市公司股东大会 规则》等法律、法规、规范性文件和《公司章程》的规定。 二、会议出席情况 参加本次会议的股东及股东代理人共133人，代表公司有表决权的股份 237,307,781股，占公司有表决权股份总数的28.7787%。其中：1、出席本次现场 会议的股东及股东代表共3人，代表有表决权的股份数231,250,495股，占公司有 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或 ...

北京市中伦律师事务所 关于烟台东诚药业集团股份有限公司 2024 年度股东大会的 法律意见书 致：烟台东诚药业集团股份有限公司 根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共和 国证券法》及中国证券监督管理委员会发布的《上市公司股东大会规则》等规定， 北京市中伦律师事务所（以下简称本所）接受烟台东诚药业集团股份有限公司（以 下简称公司）的委托，指派本所律师对公司 2024 年度股东大会（以下简称本次 股东大会）进行见证并就相关事项出具本法律意见书。 为出具本法律意见书，本所律师查阅了公司提供的相关文件，包括但不限于： 1. 现行《烟台东诚药业集团股份有限公司章程》（以下简称《公司章程》）； 2. 公司于 2025 年 2 月 27 日刊登在深圳证券交易所网站（www.szse.cn）、 巨潮资讯网（www.cninfo.com.cn）的第六届董事会第九次会议决议公告、关于召 开本次股东大会的通知； 3. 公司本次股东大会股权登记日（2025 年 3 月 24 日）的股东名册、出席现 场会议的股东的到会登记记录及凭证资料； 4. 公司本次股东大会的会议文件。 1 法律意见书 在本法律意见书中， ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [8] Core Views - The company reported a revenue of 2.869 billion yuan in 2024, a year-on-year decrease of 12.42%, and a net profit attributable to shareholders of 184 million yuan, also down 12.35% year-on-year. The adjusted net profit decreased significantly by 62.69% to 79 million yuan. However, in the fourth quarter, the company achieved a revenue of 707 million yuan, a year-on-year increase of 2.35%, and a net profit of 17 million yuan, marking a turnaround from losses [5][14] Summary by Sections Business Performance - The company's raw material drug business saw a revenue of 1.255 billion yuan in 2024, down 25.17% year-on-year, primarily due to a decline in the sales price of heparin sodium. The demand for heparin raw materials is improving, although the export price has been affected by raw material costs. The nuclear medicine business remained stable, with revenues from 18F-FDG at 421 million yuan (up 0.25% year-on-year) and from cloud injection solutions at 231 million yuan (down 5.48% year-on-year) [15] Nuclear Medicine Development - The company has a leading position in nuclear medicine facilities and product layout. It has received approval for the launch of technetium-99m labeled drugs and has several products in the III phase of clinical trials. The company operates multiple nuclear medicine centers, covering 93.5% of the domestic population's nuclear medicine needs [16] Future Projections - The company is expected to see revenues of 3.098 billion yuan, 3.361 billion yuan, and 3.661 billion yuan for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 7.99%, 8.50%, and 8.93%. The net profit attributable to shareholders is projected to be 237 million yuan, 264 million yuan, and 297 million yuan for the same years, with growth rates of 28.97%, 11.54%, and 12.23% respectively. The earnings per share (EPS) are expected to be 0.29 yuan, 0.32 yuan, and 0.36 yuan [17]

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company's short-term performance is impacted by increased costs, but the innovative nuclear medicine research is progressing steadily [5][7] - In 2024, the company achieved a revenue of 2.869 billion yuan, a decrease of 12.42%, and a net profit attributable to shareholders of 184 million yuan, down 12.35% [7] - The company anticipates marginal improvement in 2025 as the demand for heparin raw materials gradually recovers [7] Financial Summary - The latest closing price is 13.25 yuan, with a one-year high of 16.29 yuan and a low of 11.28 yuan [3] - The current P/E ratio is 59.44, and the P/B ratio is 2.44 [3] - The total share capital is 8.25 billion shares, with a total market value of 10.926 billion yuan [3] Profit Forecast - Revenue projections for 2025 to 2027 are 3.141 billion yuan, 3.433 billion yuan, and 3.737 billion yuan, with growth rates of 9.5%, 9.3%, and 8.9% respectively [6] - Net profit attributable to shareholders is expected to be 235 million yuan, 286 million yuan, and 339 million yuan for the same years, with growth rates of 28.1%, 21.2%, and 18.8% respectively [6] - The estimated P/E ratios for 2025, 2026, and 2027 are 46.4, 38.3, and 32.2 respectively [6]

Investment Rating - The report assigns an initial "Buy" rating for the company [1]. Core Views - The company is entering a harvest period for its nuclear medicine platform, with stable revenue contributions expected from its core heparin business starting in 2025 [7]. - The nuclear medicine industry is experiencing demand expansion, with a stable duopoly supply structure, and the company is well-positioned to benefit from this growth [7]. - The company has a comprehensive supply network in the nuclear medicine sector, which enhances its competitive advantage compared to international peers [7]. - The company’s innovative nuclear medicine pipeline is expected to yield commercial returns in the near future, with several products in advanced clinical stages [7]. - The financial forecast indicates a recovery in revenue and profit from 2025 onwards, driven by the commercialization of new nuclear medicine products [7]. Summary by Sections 1. Company Overview - The company is a leading innovator in nuclear medicine research and production, with a comprehensive business model covering raw materials, formulations, nuclear medicine, and health products [14]. 2. Nuclear Medicine Industry - The nuclear medicine market is characterized by high entry barriers and strong growth potential, primarily used for imaging diagnostics and tumor treatment [31]. - The global nuclear medicine market is projected to grow at a CAGR of 11.5% from 2024 to 2033, with significant opportunities in China, where the market is expected to grow at a CAGR of 32.4% from 2021 to 2025 [7]. 3. Company’s Nuclear Medicine Pipeline - The company has a robust pipeline of nuclear medicine products, with several candidates in late-stage clinical trials, including treatments for prostate cancer and other malignancies [7]. - The company’s nuclear medicine segment achieved revenue of 1.01 billion yuan in 2024, with a gross margin of 69.1%, indicating strong profitability in this area [22]. 4. Financial Projections - Revenue projections for 2025-2027 are 32.2 billion yuan, 37.1 billion yuan, and 41.9 billion yuan, respectively, with corresponding net profits of 2.2 billion yuan, 3.2 billion yuan, and 4.0 billion yuan [7]. - The current P/E ratios for the company are projected to be 50, 34, and 27 for the years 2025, 2026, and 2027, respectively, suggesting potential undervaluation given the expected growth [7].